stars 1 stars 2 stars 3

Innovative and flexible technology for rapid and cost-effective approval of biosimilars to market. With over 30 years of experience in creating new drugs, chemicals, biologicals, and biosimilars, we are now creating a novel platform that guarantees the lowest cost and time to market—-We guarantee it. Novel 351k provides innovative and flexible technology for rapid and cost-effective approval of biosimilars to market. We provide innovation and speed to existing commercial models that reduce the time for pharma and biotech partners to manage their portfolios and development costs efficiently and effectively by bringing approved biosimilars to the process of licensing stages the market more rapidly. Our core strength is complemented by decades of experience working through the novelty of the regulatory path.

View Top Employees from Novel351k
Website https://351k.com
Employees 3 (3 on RocketReach)
Industry Biotechnology Research

Novel351k Questions

Chuck Mueller is the CFO of Novel351k.

3 people are employed at Novel351k.

Top Novel351k Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
talentculture2022
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users